99 related articles for article (PubMed ID: 6146330)
1. Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension.
Bihari D; Westaby D; Gimson A; Crossley I; Harry J; Williams R
Br J Clin Pharmacol; 1984 Jun; 17(6):753-7. PubMed ID: 6146330
[TBL] [Abstract][Full Text] [Related]
2. Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model.
Kroeger RJ; Groszmann RJ
Gastroenterology; 1985 Apr; 88(4):896-900. PubMed ID: 2857673
[TBL] [Abstract][Full Text] [Related]
3. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension.
Westaby D; Bihari DJ; Gimson AE; Crossley IR; Williams R
Gut; 1984 Feb; 25(2):121-4. PubMed ID: 6693039
[TBL] [Abstract][Full Text] [Related]
4. Comparative haemodynamic effects of betaxolol and propranolol in patients with cirrhosis.
Braillon A; Lee SS; Valla D; Geoffroy P; Sauvanet JP; Lebrec D
Scand J Gastroenterol; 1988 Aug; 23(6):691-5. PubMed ID: 2902683
[TBL] [Abstract][Full Text] [Related]
5. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
[TBL] [Abstract][Full Text] [Related]
6. Daily variation in portal blood flow and the effect of propranolol administration in a randomized study of patients with cirrhosis.
Alvarez D; de las Heras M; Abecasis R; Terg R; Gerona S; Albornoz L; Galdame O; Torres J; Mastai R
Hepatology; 1997 Mar; 25(3):548-50. PubMed ID: 9049196
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic responses to selective blockade of beta 2- and beta 1-adrenoceptors in conscious rats with cirrhosis.
Komeichi H; Moreau R; Cailmail S; Gaudin C; Lebrec D
J Hepatol; 1994 Nov; 21(5):779-86. PubMed ID: 7890894
[TBL] [Abstract][Full Text] [Related]
8. Effects of a selective beta 2-blocker (ICI 118,551) on hepatic haemodynamics in the cirrhotic and non-cirrhotic rat.
Jenkins SA; Baxter JN; Johnston JN; Devitt P; Shields R
Br J Surg; 1985 Aug; 72(8):653-6. PubMed ID: 2862948
[TBL] [Abstract][Full Text] [Related]
9. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
Sekiyama T; Komeichi H; Nagano T; Ohsuga M; Terada H; Katsuta Y; Satomura K; Aramaki T
Arzneimittelforschung; 1997 Apr; 47(4):353-5. PubMed ID: 9150854
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade.
Dahlöf B; Andrén L; Svensson A; Hansson L
J Hypertens Suppl; 1983 Dec; 1(2):112-5. PubMed ID: 6152739
[TBL] [Abstract][Full Text] [Related]
11. Beta adrenergic stimulation and blockade in cirrhosis: effects on azygos vein blood flow and portal hemodynamics.
Weinshel EH; Altszuler HM; Raicht RF; Sedlis SP
Am J Med Sci; 1994 Jun; 307(6):396-400. PubMed ID: 7911005
[TBL] [Abstract][Full Text] [Related]
12. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
Bosch J; Kravetz D; Rodes J
Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
[TBL] [Abstract][Full Text] [Related]
14. Effect and mechanism of action of isosorbide-5-mononitrate.
Hayes PC; Westaby D; Williams R
Gut; 1988 Jun; 29(6):752-5. PubMed ID: 3384359
[TBL] [Abstract][Full Text] [Related]
15. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Hobolth L; Bendtsen F; Hansen EF; Møller S
Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
[TBL] [Abstract][Full Text] [Related]
16. Portal hemodynamics during nitroglycerin administration in cirrhotic patients.
Garcia-Tsao G; Groszmann RJ
Hepatology; 1987; 7(5):805-9. PubMed ID: 3115881
[TBL] [Abstract][Full Text] [Related]
17. [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis].
Hüppe D; Jäger D; Tromm A; Tunn S; Barmeyer J; May B
Dtsch Med Wochenschr; 1991 May; 116(22):841-5. PubMed ID: 2036943
[TBL] [Abstract][Full Text] [Related]
18. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation.
Fernández M; Pizcueta P; García-Pagán JC; Feu F; Cirera I; Bosch J; Rodés J
Hepatology; 1993 Aug; 18(2):389-93. PubMed ID: 8340068
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
20. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats.
Nevens F; Pizcueta MP; Fernández M; Bosch J; Rodés J
Hepatology; 1991 Dec; 14(6):1174-8. PubMed ID: 1959867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
